BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31358662)

  • 21. Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.
    Jemaà M; Manic G; Lledo G; Lissa D; Reynes C; Morin N; Chibon F; Sistigu A; Castedo M; Vitale I; Kroemer G; Abrieu A
    Oncotarget; 2016 Jan; 7(1):885-901. PubMed ID: 26637805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor.
    Sun Y; Chen Z; Liu G; Chen X; Shi Z; Feng H; Yu L; Li G; Ding K; Huang H; Zhang Z; Xu S
    Bioorg Chem; 2024 Feb; 143():107053. PubMed ID: 38159497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.
    Martinez R; Blasina A; Hallin JF; Hu W; Rymer I; Fan J; Hoffman RL; Murphy S; Marx M; Yanochko G; Trajkovic D; Dinh D; Timofeevski S; Zhu Z; Sun P; Lappin PB; Murray BW
    PLoS One; 2015; 10(9):e0138616. PubMed ID: 26398286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell lung cancer.
    Chen X; Yu C; Gao J; Zhu H; Cui B; Zhang T; Zhou Y; Liu Q; He H; Xiao R; Huang R; Xie H; Gao D; Zhou H
    Theranostics; 2018; 8(9):2348-2360. PubMed ID: 29721084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
    Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
    Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TTK/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myeloma.
    Longo LVG; Hughes T; McNeil-Laidley B; Cottini F; Hilinski G; Merritt E; Benson DM
    Haematologica; 2024 Feb; 109(2):578-590. PubMed ID: 37496433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity.
    Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Kojima E; Mitsuoka Y; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Yoshizawa H; Murai H; Nakamura Y
    Bioorg Med Chem; 2015 May; 23(9):2247-60. PubMed ID: 25801152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular basis underlying resistance to Mps1/TTK inhibitors.
    Koch A; Maia A; Janssen A; Medema RH
    Oncogene; 2016 May; 35(19):2518-28. PubMed ID: 26364596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hsp90 regulates the tumorigenic function of tyrosine protein kinase in osteosarcoma.
    Yao ZP; Zhu H; Shen F; Gong D
    Clin Exp Pharmacol Physiol; 2022 Mar; 49(3):380-390. PubMed ID: 34767669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
    Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
    Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.
    Wu ZX; Yang Y; Wang G; Wang JQ; Teng QX; Sun L; Lei ZN; Lin L; Chen ZS; Zou C
    Cancer Sci; 2020 Aug; 111(8):2872-2882. PubMed ID: 32478948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A tyrosine kinase inhibitor, beta-hydroxyisovalerylshikonin, induced apoptosis in human lung cancer DMS114 cells through reduction of dUTP nucleotidohydrolase activity.
    Kajimoto S; Horie M; Manabe H; Masuda Y; Shibayama-Imazu T; Nakajo S; Gong XF; Obama T; Itabe H; Nakaya K
    Biochim Biophys Acta; 2008 Jan; 1782(1):41-50. PubMed ID: 18078828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
    Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
    Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor.
    M Serafim RA; da Silva Santiago A; Schwalm MP; Hu Z; Dos Reis CV; Takarada JE; Mezzomo P; Massirer KB; Kudolo M; Gerstenecker S; Chaikuad A; Zender L; Knapp S; Laufer S; Couñago RM; Gehringer M
    J Med Chem; 2022 Feb; 65(4):3173-3192. PubMed ID: 35167750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.
    Liu Y; Lang Y; Patel NK; Ng G; Laufer R; Li SW; Edwards L; Forrest B; Sampson PB; Feher M; Ban F; Awrey DE; Beletskaya I; Mao G; Hodgson R; Plotnikova O; Qiu W; Chirgadze NY; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
    J Med Chem; 2015 Apr; 58(8):3366-92. PubMed ID: 25763473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.